I. Introduction
( + )-Trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide (U50,488) is a highly selective agonist at the K opioid receptor . The pharmacological profile of x opioid receptor agonists in-* To whom all correspondence should be addressed.
cludes activity as diuretics (Leander, 1983) , as anticonvulsants (Von Voigtlander and Lewis, 1988) , as analgesics , and perhaps as mu receptor antagonists (Porreca and Tortella, 1987; Sheldon et al., 1987) . Other data suggest that K opioid agonists in man are psychotomimetic (Pfeiffer et al., 1986) , and that K agonists may be beneficial in the treatment of acute brain and spinal cord injury . Most studies employing U50,488 have used the racemate. The relative contributions of the two enantiomers to the observed pharmacological effects is unknown, and complicates the interpretation of results, especially since it is well known that enantiomers often produce different and sometimes opposite effects (AriEns, 1987; . For this reason De Costa et al. (1987) synthesized optically pure enantiomers of U50,488.
In our studies we define ~ binding sites as the residual binding sites remaining after suppression of/z and 6 binding sites (Kosterlitz et al., 1981) . Initial binding experiments using [3H](-)-bremazocine ([3H]BRM) to label ~ binding sites of guinea pig brain indicated that (-)-(1S,2S)-U50,488 was much more potent than (+)-(1R,2R)-U50,488 in displacing binding (De Costa et al., 1987) . In a more detailed study, this was confirmed using [3H]5o47o48/~-(-)-N-methyl-N-[7-(1-pyrrolidinyl)-l-oxaspiro(4,5)dec-8-yl]phenylbenzeneacetamide ([3H]U69,593) to label K binding sites (Lahti et al., 1985; Rothman et al., 1988b) . In this paper we examine the interaction of (_+)-cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide (abbreviated ( _+ )-cis-I) and its enantiomers (abbreviated (+)-cis-I and (-)-cis-I) with ~ binding sites labeled by [3H]U69,593 and [3H]BRM. The pharmacological activity of (_+)-cis-I and the two enantiomers trans-U50,488 were also studied in rhesus monkeys using a drug discrimination paradigm and a test for analgesia. The results demonstrate that in tests of analgesia and drug discrimination, (-)-(1S,2S)-U50,488 is more potent than (+)-(1R,2R)-U50,488, and further, although (_+)-cis-I substitutes for ethylketocyclazocine (EKC) in the rhesus monkey, it is not an antinociceptive agent.
Materials and methods

Pharmacological studies
Subjects
Four male and two female rhesus monkeys (Macaca mulatta) weighing between 6 and 10 kg were housed individually and allowed free access to water. The two male monkeys in the drug discrimination experiment were maintained at 85% of their free-feeding weights by regulating the number of Purina Monkey Chow biscuits they received daily. The four monkeys in the tail withdrawal experiments were allowed free access to food in the home cage. All monkeys received fresh fruit and vitamins occasionally.
Drug discrimination procedure
Drug discrimination experiments were conducted in sound-attenuated, ventilated isolation chambers equipped with two response levers located on either side of a food receptacle and within easy reach of a seated monkey. An array of stimulus lights was located directly above the response levers and a dispenser that could deliver food pellets was located outside the chamber.
Monkeys were seated in Plexiglas primate chairs during daily experimental sessions that lasted 2 h or less. Both monkeys had been trained to discriminate between s.c. injections of EKC (0.0032 mg/kg) and saline. The multiple-cycle training and testing procedures used in the present study have been described elsewhere (Bertalimo et al., 1982) . Training sessions consisted of between two and six discrete 15 min cycles; each cycle consisted of a 10 min time-out period during which the chamber was dark and lever presses had no programmed consequence, and a 5 min response period during which the stimulus lights were illuminated and 100 consecutive responses on the injection-appropriate lever (left lever, EKC-appropriate; right lever, saline-appropriate) resulted in delivery of 10 Noyes 300 mg banana-flavored pellets. When 100 correct responses were made within 5 min, the stimulus lights were extinguished for the remainder of the response period. On some training days a single injection of EKC was administered prior to one of the cycles and that cycle was followed by a single non-injection (sham) cycle during which only responding on the EKCappropriate lever produced food. The number of saline injection cycles that preceded the EKC injection cycle varied across days and on some training days sham or saline was administered prior to all cycles.
Test sessions were identical to training sessions except that 100 consecutive responses on either level produced 10 food pellets, saline always was administered prior to the first cycle, and drug was administered prior to subsequent cycles. Increasing doses of drug were administered so that the cumulative dose increased by 1/2 or 1/4 log unit per cycle (Bertalimo et al., 1982) .
Tail withdrawal procedure and apparatus
The tail withdrawal procedure used in the present study to measure antinociception was similar to that described previously (Dykstra and Woods, 1986) . During weekly 3 h sessions, monkeys were restrained loosely at the neck and arms while seated in Plexiglas primate chairs. For tests of tail withdrawal latency, the lower 10-12 cm of the shaved tail was immersed in a thermos containing water at 40, 50 or 55 ° C. The latency until the tail was withdrawn from the thermos was recorded for each monkey at each temperature. If the tail was not withdrawn within 20 s (cut-off latency) the experimenter removed the tail from the thermos and a latency of 20 s was recorded.
Experimental sessions began with several exposures to 40 °C water. Four monkeys were tested consecutively and the time between immersions for individual monkeys was 5 min. It has been reported that 40°C water does not produce tail withdrawal in rhesus monkeys (Dykstra and Woods, 1986; Dykstra et al., 1987) and in the present study monkeys generally did not withdrawn their tails from 40 °C water. However, if a monkey failed to keep its tail in 40 °C water for 20 s on at least three of four immersions, that animal was not tested further. In the subsequent pre-test component tails were immersed in 40, 50 and 55°C water. The order in which the three temperatures were presented varied among subjects. If the latencies for tail withdrawal in the pre-test component were at or near 20 s for 40 °C water and less than 5 s for 55 °C water, monkeys received the test compound.
The test was identical to the pre-test, except that monkeys received s.c. injections of drug 10 min prior to tail immersion. The time between immersions for individual subjects was 5 min and the order in which temperatures were presented varied among subjects and across cycles. The inter-injection interval was 30 rain and a maximum of four doses were studied in a single session (i.e. 2 h total time). The cumulative dosing procedure was similar to that described above.
Receptor binding assays
Guinea pig brain membranes were pretreated with the site directed acylating agents 2-(4-ethoxybenzyl)-l-diethylaminoethyl-5-isothiocyanatobenzimidazole-HC1 (BIT) and N-phenyl-N-[1-(2-(4-isothiocyanato)phenethyl)-4-piperidinyl]-propanamide-HC1 (FIT) to deplete the membranes of /~ and 6 receptors (Rothman et al., 1985) . x Binding sites were labeled with both [3H]U69,593 and [3H]BRM. The [3H]U69,593 binding assay proceeded as previously described (Rothman et al., 1988b) . Briefly, incubations were for 60 min at 37°C in 50 mM Tris-HCl, pH 7.4, containing 3 mM MnC12, 0.1 mg/ml bovine serum albumin, and a protease inhibitor cocktail containing bacitracin (100 ~g/ml), bestatin (10 /ag/ml), leupetin (4 ~g/ml), chymostatin (2 ~tg/ml) and captopril (1 /ag/ml). Non-specific binding was defined using 1 /~M U69,593. The [3H]BRM binding assay proceeded according to published protocols (Rothman et al., 1985) , except that the assay was conducted without NaCI. Nonspecific binding was defined using 1 /~M ( -)-bremazocine, [ 3 H][D_Ala2,D_Leu 5 ]enkephalin ([ 3 H]DADL) and [ 3 H]6/3-fluoro-6-desoxy-oxymorphone ([3H]FOXY) binding assays were conducted, using rat brain membranes, as previously described (Rothman et al., 1988a,c) . In these assays, the non-specific binding was defined using 10 /xM levallorphan. Proteins were measured as described (Lowry et al., 1951) .
Binding surfaces were generated and analyzed as previously described (Rothman et al., 1988d; Rothman, 1986) . Briefly, two concentrations of 3H ligand were each displaced by varying concentrations of test drugs. The combined data were fit to either a one site or two site binding model using MLAB (Knott et al., 1972) for the best-fit parameter estimates. MLAB fits the data according to a weighted non-linear least squares curve fitting algorithm. 
Chemicals
Results
Drug discrimination studies
Monkeys trained to discriminate between s.c. injections of 0.0032 mg/kg EKC and saline generalized to EKC in a dose-related manner with the smallest dose of EKC that produced complete generalization being 0.0018 mg/kg (data not shown).
(-)-(1S,2S)-U50,488 and (+)-(1R,2R)-U50,488, (_+)-U50,488 and (+)-cis-I substituted
completely for the EKC discriminative stimulus in that all four drugs produced responding exclusively in the EKC appropriate lever ( fig. 1, 
left panel). The order of potency as discriminative stimuli was (-)-(1S,2S)-U50,488 > (_+)-U50A88 > (_+)-cis-I > (+)-(1R,2R)-U50,488
. At doses that produced EKC-appropriate responding, none of the drugs altered rates of lever pressing (data not shown). There was insufficient quantities of (+)-cis-I and (-)-cis-I for in vivo testing.
Tail withdrawal
The latency for tail withdrawal from 40, 50 and 55°C water was temperature-dependent. The average latencies for tail withdrawal during pre-test components was 17.7, 1.7 and 1. 
Ligand binding data
The relatively potent ability of (+_)-cis-I to substitute for EKC in the drug discrimination studies (EDs0 about 0.5 mg/kg) and its virtual inactivity in the test for antinociception, led us to examine the interaction of (+_)-cis-I and its enantiomers with x binding sites labeled by fig. 2 (78 data points) were fit to the two site competitive model. The best-fit parameter estimates are reported above, and generated the lines in fig. 2 . The sumof-squares was 0.152. When the data were fit to a one site model, the sum-of-squares was 0.779, which was significantly worse (P < 0.001). The binding parameters of (-)-(1S,2S)-U50,488 and (+)-(1R,2R)-U50,488 were used to predict the displacement which would be observed for (+)-U50,488. As shown in in fig. 2C , the lines generated by these binding parameters fit the observed data well. Each parameter value is +S.D.
Parameter
Site 1 was displaced by the enantiomers of (+)-cis-I. The displacement curves were fit to the two parameter logistic equation (Rodbard et al., 1976) for the IC50, and the Kis calculated using the equation: K i = IC50/(1 +l/Ka). a The Kis on the enantiomers of U50,488 reported in another publication (Rothman et al., 1988b) (Rothman et al., 1988b) . Thus the enantiomers of (_+)-cis-I exhibit about the same degree of enantioselectively as the enantiomers of U50,488, but with Kds about one order of magnitude higher.
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Discussion
Although U50,488 (a racemic compound) has been used as a selective ~c agonist for several years, few studies have examined the pharmacological activity of its enantiomers, (-)-(1S,2S)-U50,488, (+)-(1R,2R)-U50,488, (-)-cis-I and (+)-cis-I. The major finding of this paper is that the biological activity related to activation of • receptors by U50,488 appears to reside primarily in the (-)-(1S,2S)enantiomer. In drug discrimination studies ( fig. 1 ), (-)-(1S,2S)-U50,488 is about 100 times more potent than (+)-(1R,2R)-U50,488. Similarly, in a test of analgesia, whereas (-)-(1S,2S)-U50,488 is active (EDs0 less than 1 mg/kg), (+)-(1R,2R)-U50,488 is virtually inactive. The racemate, U50,488, was active in both paradigms, having a potency intermediate between that of its two enantiomers.
An interesting finding to emerge from this study is that (_+)-cis-I potently substituted for EKC in the drug discrimination experiments, yet was inactive in the tail withdrawal tests. This finding prompted the examination of the interaction of (_+)-cis-I and its two enantiomers with/~, 8 and K binding sites in vitro. As described previously (Kosterlitz et al., 1981) , we define a ~ binding site as the residual [3H]BRM binding remaining after suppression of/~ and 8 binding sites.
Previous studies demonstrated that, using membranes depleted of # and 6 binding sites by pretreatment with the site-directed acylating agents BIT and FIT respectively, [3H] BRM labels a population of non-/~, non-6 binding sites with some of the characteristics of K receptors (Rothman et al., 1985) . In contrast, (-)-(1S,2S)-U50,488 binds about ten times more potently to the population of non-~t, non-~ binding sites labeled by [3H]U69,593 (K d about 2 nM). This, and the fact that pretreatment of membranes with the acylating agent 1S, 2S-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl) (Ari6ns, 1987; .
( , consistent with the intermediate potency of (_+)-cis-I observed in the drug discrimination studies. These in vitro results suggest that the discriminative cue is mediated by the population of x receptors labeled by [3H]U69,593. However, it is still necessary to show that this effect is naloxone reversible. Because (-)-cis-I and (+)-cis-I bind with reasonably high affinity to haloperidol-sensitive o binding sites (Kds of 81 and 221 nM, respectively), it remains a remote possibility that this binding site is involved in the pharmacological actions of the cis-enantiomers of U50,488 observed in this study (De Costa et al., in press) .
The failure of ( + )-cis-I to produce antinociception might be taken as evidence that different populations of ~ receptors mediate the discriminative cue and antinociception. However, (+)-(1R,2R)-U50,488 was also inactive in the tailwithdrawal test, which is consistent with the observation that all compounds tested in this study were ten to a hundred times more potent in the drug discrimination experiments than in the tests of analgesia. A more likely explanation for these observations is that the discriminative cue is activated at low fractional occupancy of the x receptor, whereas higher fractional occupancy is required to produce antinociception. Taken collectively, the results reported here, and summarized in table 3, suggest that the receptor-related pharmacological activity of U50,488 resides primarily in the (-)-(1S,2S)-enantiomer, and that (+)-(1R,2R)-U50,488 might possess weak activity at /~ receptors, consistent with data published by Von Voigtlander and Lewis (1988) . Examination of the interaction of the four stereoisomers of U50,488 with the population of non-/~, non-8 binding sites labeled by [3H]BRM and those labeled by [3H]U69,593 provides further evidence for the existence of at least three classes of x binding sites in guiea pig brain, and suggest that the pharmacological actions of U50,488 result from activation of the x receptor labeled by [3H]U69,593. The structure-activity profile and functional significance of the x binding sites labeled by [3H]BRM are currently under investigation.
